Timing of Pharmacological Treatment for Patent Ductus Arteriosus and Risk of Secondary Surgery, Death or Bronchopulmonary Dysplasia: A Population-Based Cohort Study of Extremely Preterm Infants

被引:28
作者
Gudmundsdottir, Anna [1 ]
Johansson, Stefan [2 ]
Hakansson, Stellan [4 ]
Norman, Mikael [3 ]
Kallen, Karin [5 ]
Bonamy, Anna-Karin [1 ,2 ]
机构
[1] Karolinska Inst, Dept Womens & Childrens Hlth, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Clin Epidemiol Unit, Dept Med Solna, SE-17176 Stockholm, Sweden
[3] Karolinska Inst, Dept Clin Sci Intervent & Technol, SE-17176 Stockholm, Sweden
[4] Umea Univ, Dept Clin Sci Pediat, Umea, Sweden
[5] Lund Univ, Inst Clin Sci, Ctr Reprod Epidemiol, Lund, Sweden
基金
瑞典研究理事会;
关键词
Patent ductus arteriosus; Extremely preterm infants; Pharmacological treatment; Timing; Outcome; Surgical treatment; Epidemiology; BIRTH-WEIGHT INFANTS; SPONTANEOUS CLOSURE; INDOMETHACIN PROPHYLAXIS; IBUPROFEN; TRIAL;
D O I
10.1159/000367887
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: The optimal timing of pharmacological treatment for patent ductus arteriosus (PDA) in extremely pre-term infants is unknown. Objective: To investigate whether timing of pharmacological PDA treatment is associated with a risk of secondary PDA surgery or death before 3 months of age, or bronchopulmonary dysplasia (BPD) in extremely preterm infants. Methods: In this population-based cohort of infants born before 27 gestational weeks in Sweden in 2004-2007, 290/585 infants (50%) received pharmacological PDA treatment. Cox proportional hazards regression estimated the hazard ratio (HR, with 95% confidence interval, Cl) of secondary PDA surgery or death as a composite outcome in relation to postnatal age at the start of pharmacological treatment: early (0-2 days); intermediate (3-6 days); late (>= 7 days). Furthermore, the odds ratio (OR, with 95% Cl) of BPD was estimated in relation to postnatal age at PDA treatment by conditional logistic regression. Results: The median postnatal age at the start of pharmacological PDA treatment was 4 days. 102 infants had secondary PDA surgery. Timing of PDA treatment was not associated with risk of PDA surgery or death; adjusted HRs were 0.89 (95% CI 0.57-1.39) after an intermediate start and 1.10(95% CI 0.53-2.28) after a late start, compared to an early start of treatment. Compared to the early start of PDA treatment, the intermediate start was not associated with any risk of BPD, while late PDA treatment was associated with a lower BPD risk; adjusted ORs were 0.83 (95% CI 0.42-1.64) and 0.28 (95% CI 0.13-0.61), respectively. Conclusion: Timing of pharmacological PDA treatment after extremely preterm birth is not associated with the risk of secondary PDA surgery or death. Moreover, expectant PDA management is not associated with an increased risk of BPD. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:87 / 92
页数:6
相关论文
共 25 条
[1]   Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm infants study in Sweden (EXPRESS) [J].
Austeng, Dordi ;
Blennow, Mats ;
Ewald, Uwe ;
Fellman, Vineta ;
Fritz, Thomas ;
Hellstrom-Westas, Lena ;
Hellstrom, Ann ;
Holmgren, Per Ake ;
Holmstrom, Gerd ;
Jakobsson, Peter ;
Jeppsson, Annika ;
Johansson, Kent ;
Kallen, Karin ;
Lagercrantz, Hugo ;
Laurini, Ricardo ;
Lindberg, Eva ;
Lundqvist, Anita ;
Marsal, Karel ;
Nilstun, Tore ;
Norden-Lindeberg, Solveig ;
Norman, Mikael ;
Olhager, Elisabeth ;
Oestlund, Ingrid ;
Serenius, Fredrik ;
Simic, Marija ;
Sjors, Gunnar ;
Stigson, Lennart ;
Stjernqvist, Karin ;
Stromberg, Bo ;
Tornqvist, Kristina ;
Wennergren, Margareta ;
Wallin, Agneta ;
Westgren, Magnus .
ACTA PAEDIATRICA, 2010, 99 (07) :978-992
[2]   Patent ductus arteriosus and respiratory outcome in premature infants [J].
Bancalari, E ;
Claure, N ;
Gonzalez, A .
BIOLOGY OF THE NEONATE, 2005, 88 (03) :192-201
[3]   NEONATAL NECROTIZING ENTEROCOLITIS - THERAPEUTIC DECISIONS BASED UPON CLINICAL STAGING [J].
BELL, MJ ;
TERNBERG, JL ;
FEIGIN, RD ;
KEATING, JP ;
MARSHALL, R ;
BARTON, L ;
BROTHERTON, T .
ANNALS OF SURGERY, 1978, 187 (01) :1-7
[4]   One-Year Survival of Extremely Preterm Infants After Active Perinatal Care in Sweden [J].
Blennow, Mats ;
Ewald, Uwe ;
Fritz, Tomas ;
Holmgren, Per Ake ;
Jeppsson, Annika ;
Lindberg, Eva ;
Lundqvist, Anita ;
Lindeberg, Solveig Norden ;
Olhager, Elisabeth ;
Ostlund, Ingrid ;
Simic, Marija ;
Sjoers, Gunnar ;
Stigson, Lennart ;
Fellman, Vineta ;
Hellstrom-Westas, Lena ;
Norman, Mikael ;
Westgren, Magnus ;
Holmstrom, Gerd ;
Laurini, Ricardo ;
Stjernqvist, Karin ;
Kallen, Karin ;
Lagercrantz, Hugo ;
Marsal, Karel ;
Serenius, Fredrik ;
Wennergren, Margareta ;
Nilstun, Tore ;
Olausson, Petra Otterblad ;
Stromberg, Bo .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (21) :2225-2233
[5]   Recommendations for the postnatal use of indomethacin: An analysis of four separate treatment strategies [J].
Clyman, RI .
JOURNAL OF PEDIATRICS, 1996, 128 (05) :601-607
[6]   The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia [J].
Clyman, Ronald I. .
SEMINARS IN PERINATOLOGY, 2013, 37 (02) :102-107
[7]  
Cooke L, 2003, Cochrane Database Syst Rev, pCD003745
[8]   Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies) [J].
Costeloe, Kate L. ;
Hennessy, Enid M. ;
Haider, Sadia ;
Stacey, Fiona ;
Marlow, Neil ;
Draper, Elizabeth S. .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
[9]   The fate of ductus arteriosus in infants at 23-27 weeks of gestation: from spontaneous closure to ibuprofen resistance [J].
Dani, Carlo ;
Bertini, Giovanna ;
Corsini, Iuri ;
Elia, Serena ;
Vangi, Venturella ;
Pratesi, Simone ;
Rubaltelli, Firmino F. .
ACTA PAEDIATRICA, 2008, 97 (09) :1176-1180
[10]   Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia [J].
Ehrenkranz, RA ;
Walsh, MC ;
Vohr, BR ;
Jobe, AH ;
Wright, LL ;
Fanaroff, AA ;
Wrage, LA ;
Poole, K .
PEDIATRICS, 2005, 116 (06) :1353-1360